1. Home
  2. LCNB vs CGEN Comparison

LCNB vs CGEN Comparison

Compare LCNB & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LCNB Corporation

LCNB

LCNB Corporation

HOLD

Current Price

$17.57

Market Cap

238.1M

Sector

Finance

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$1.74

Market Cap

220.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCNB
CGEN
Founded
1877
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
238.1M
220.7M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
LCNB
CGEN
Price
$17.57
$1.74
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
27.1K
568.8K
Earning Date
01-29-2026
03-03-2026
Dividend Yield
4.99%
N/A
EPS Growth
68.04
N/A
EPS
1.63
N/A
Revenue
$90,061,000.00
$6,903,000.00
Revenue This Year
$8.39
N/A
Revenue Next Year
$4.07
$164.92
P/E Ratio
$10.82
N/A
Revenue Growth
13.66
N/A
52 Week Low
$13.34
$1.13
52 Week High
$17.84
$2.66

Technical Indicators

Market Signals
Indicator
LCNB
CGEN
Relative Strength Index (RSI) 61.78 43.71
Support Level $16.77 $2.04
Resistance Level $17.75 $2.08
Average True Range (ATR) 0.42 0.12
MACD 0.07 -0.05
Stochastic Oscillator 90.51 4.62

Price Performance

Historical Comparison
LCNB
CGEN

About LCNB LCNB Corporation

LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: